title: Use of oral VP16-213 as primary chemotherapeutic agent in treatment of gestational trophoblastic disease.
abstract: Thirty-seven patients with persistent or metastatic gestational trophoblastic disease were treated with oral etoposide (VP16-213). All responded well and achieved permanent remission. The hematologic toxicity was mild. Alopecia was present in all patients. Etoposide is an effective drug against trophoblastic disease. In patients who have received chemotherapy for long periods oral etoposide would eliminate the problem of venous access.
mesh_terms: D000284:Administration, Oral; D006063:Chorionic Gonadotropin / Q000097:blood; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010050:Ovarian Function Tests; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011247:Pregnancy; D014328:Trophoblastic Neoplasms / Q000097:blood / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy*
chemical_list: D006063:Chorionic Gonadotropin; D005047:Etoposide; D011034:Podophyllotoxin